April 11, 2024EClinicalMedicine24 citationsOpen Access

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

ALAntonio Llombart‐Cussac JPJosé Manuel Pérez-García MBManuel Ruíz Borrego

Key Points

Key points are not available for this paper at this time.

Abstract

Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2-/

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper